CTI BIOPHARMA CORP

Form 4 June 06, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and A	Address of Report atthew	ing Person *	2. Issuer Name and Ticker or Trading Symbol CTI BIOPHARMA CORP [CTIC]	5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First)	(Middle)	3. Date of Earliest Transaction	(Check all applicable)				
3101 WESTERN AVENUE, SUITE 600			(Month/Day/Year) 06/04/2014	Director 10% OwneX_ Officer (give title Other (special below) EVP, Corporate Development				
	(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check				
SEATTLE,	WA 98121		Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Table I - Non-Derivative Securities A	cquired, Disposed of, or Beneficially Owne				
1.Title of	2. Transaction l	Date 2A. Deer	med 3. 4. Securities Acquire	d 5. Amount of 6. Ownership 7. Natur				

(City)	(State)	Zip) Table	I - Non-D	erivative (Secur	ities Acqu	iired, Disposed of	, or Beneficial	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)				5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	06/04/2014		S <u>(1)</u>	700	D	\$ 2.97	608,204	D	
Common Stock	06/04/2014		S <u>(1)</u>	300	D	\$ 2.975	607,904	D	
Common Stock	06/04/2014		S <u>(1)</u>	11	D	\$ 3	607,893	D	
Common Stock	06/04/2014		S <u>(1)</u>	900	D	\$ 3.005	606,993	D	
Common Stock	06/04/2014		S(1)	2,100	D	\$ 3.01	604,893	D	

Edgar Filing: CTI BIOPHARMA CORP - Form 4

Common Stock	06/04/2014	S(1)	1,200	D	\$ 3.015	603,693	D
Common Stock	06/04/2014	S(1)	2,300	D	\$ 3.02	601,393	D
Common Stock	06/04/2014	S(1)	300	D	\$ 3.025	601,093	D
Common Stock	06/04/2014	S(1)	700	D	\$ 3.03	600,393	D
Common Stock	06/04/2014	S(1)	100	D	\$ 3.035	600,293	D
Common Stock	06/04/2014	S(1)	1,189	D	\$ 3.04	599,104	D
Common Stock	06/04/2014	S <u>(1)</u>	800	D	\$ 3.045	598,304	D
Common Stock	06/04/2014	S(1)	700	D	\$ 3.05	597,604	D
Common Stock	06/04/2014	S(1)	500	D	\$ 3.06	597,104	D
Common Stock	06/04/2014	S(1)	200	D	\$ 3.07	596,904	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: CTI BIOPHARMA CORP - Form 4

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Plunkett Matthew 3101 WESTERN AVENUE, SUITE 600

EVP, Corporate Development

SEATTLE, WA 98121

Signatures

Louis A. Bianco, Attorney-in-fact For: Matthew

Plunkett 06/06/2014

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale was effected pursuant to a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3